0
0
0
Studying Suboxone Act
1/3/2024, 5:45 PM
Summary of Bill HR 4053
Bill 118 HR 4053, also known as the Studying Suboxone Act, is a piece of legislation introduced in the US Congress. The purpose of this bill is to authorize the Department of Health and Human Services to conduct a study on the effectiveness of Suboxone in treating opioid addiction.
Suboxone is a medication commonly used in medication-assisted treatment for opioid addiction. It contains a combination of buprenorphine and naloxone, which work together to reduce cravings and withdrawal symptoms in individuals struggling with opioid dependence.
The Studying Suboxone Act aims to gather data and research on the use of Suboxone in treating opioid addiction, including its effectiveness, safety, and potential side effects. This information will be crucial in informing policymakers and healthcare providers on the best practices for treating opioid addiction and reducing the harm caused by the opioid epidemic. Overall, Bill 118 HR 4053 seeks to improve our understanding of Suboxone as a treatment option for opioid addiction and to ultimately improve outcomes for individuals struggling with substance use disorders. It highlights the importance of evidence-based research in addressing the ongoing public health crisis of opioid addiction in the United States.
Suboxone is a medication commonly used in medication-assisted treatment for opioid addiction. It contains a combination of buprenorphine and naloxone, which work together to reduce cravings and withdrawal symptoms in individuals struggling with opioid dependence.
The Studying Suboxone Act aims to gather data and research on the use of Suboxone in treating opioid addiction, including its effectiveness, safety, and potential side effects. This information will be crucial in informing policymakers and healthcare providers on the best practices for treating opioid addiction and reducing the harm caused by the opioid epidemic. Overall, Bill 118 HR 4053 seeks to improve our understanding of Suboxone as a treatment option for opioid addiction and to ultimately improve outcomes for individuals struggling with substance use disorders. It highlights the importance of evidence-based research in addressing the ongoing public health crisis of opioid addiction in the United States.
Read the Full Bill
Current Status of Bill HR 4053
Bill HR 4053 is currently in the status of Bill Introduced since June 13, 2023. Bill HR 4053 was introduced during Congress 118 and was introduced to the House on June 13, 2023. Bill HR 4053's most recent activity was Referred to the Subcommittee on Health. as of June 16, 2023
Bipartisan Support of Bill HR 4053
Total Number of Sponsors
1Democrat Sponsors
1Republican Sponsors
0Unaffiliated Sponsors
0Total Number of Cosponsors
6Democrat Cosponsors
2Republican Cosponsors
4Unaffiliated Cosponsors
0Policy Area and Potential Impact of Bill HR 4053
Primary Policy Focus
HealthAlternate Title(s) of Bill HR 4053
Studying Suboxone Act
Studying Suboxone Act
To provide for the review of the scheduling under the Controlled Substances Act of buprenorphine-naloxone combination products, and for other purposes.
Comments
Sponsors and Cosponsors of HR 4053
Latest Bills
RISE Act
Bill S 3589August 14, 2026
Federal Building Threat Notification Act
Bill S 2542August 14, 2026
A bill to require the United States Postal Service to designate ZIP Codes for certain communities.
Bill S 4505August 14, 2026
A bill to expand the sharing of information with respect to suspected violations of intellectual property rights in trade.
Bill S 2677August 14, 2026
USMMA Athletics Act of 2026
Bill S 3266August 13, 2026
Space Commerce Advisory Committee Act
Bill S 434August 13, 2026
Diversity Jurisdiction Inflation Adjustment Act
Bill S 4850August 13, 2026
Officer John Barnes and Chief Michael Ansbro Public Safety Officers' Benefit Program Expansion Act of 2026
Bill S 3897August 13, 2026
National Defense Authorization Act for Fiscal Year 2027
Bill S 4784August 13, 2026
Cahokia Mounds Mississippian Culture Study Act
Bill S 1516August 13, 2026



